Story perspectives

FDA Grants Early Access to Daraxonrasib, Doubles Pancreatic Cancer Survival

5/7/2026

Summary

Story summary

The U.S. FDA granted early access to daraxonrasib for advanced pancreatic cancer.
Phase 3 data showed survival of 13.2 months with daraxonrasib plus chemotherapy versus 6.7 months with chemotherapy alone; a Phase 1/2 trial reported survival of 15.6 months.
Adverse events occurred in 96% of patients, in 30% mainly rash, nausea, diarrhea.
Daraxonrasib targets RAS mutated in 90% of pancreatic cancers, a disease to affect 67,000 U.S. patients and cause 52,000 deaths.

1 of 1

Story summary

The U.S. FDA granted early access to daraxonrasib for advanced pancreatic cancer.
Phase 3 data showed survival of 13.2 months with daraxonrasib plus chemotherapy versus 6.7 months with chemotherapy alone; a Phase 1/2 trial reported survival of 15.6 months.
Adverse events occurred in 96% of patients, in 30% mainly rash, nausea, diarrhea.
Daraxonrasib targets RAS mutated in 90% of pancreatic cancers, a disease to affect 67,000 U.S. patients and cause 52,000 deaths.